Sitemap > News > Neurodegenerative & Neuroelectrophysiological Disorders
Displaying 1 - 50 of 236 results
- Acorda Therapeutics Begins Second Phase 3 Clinical Trial of Fampridine-SR in Multiple Sclerosis
- BioMS Initiates Enrollment In Pivotal U.S. Phase III MS Trial
- Teva And Active Biotech To Initiate Pivotal Phase III Trial Program Of Oral Laquinimod For Relapsing Multiple Sclerosis
- Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
- Pipex Pharmaceuticals’ Oral TRIMESTA Initiates Enrollment of Phase II/III Clinical Trial for Multiple Sclerosis.
- CoMentis Receives FDA Clearance to Begin Human Clinical Trials
- Neurochem receives third recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED™)
- Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin™ for Multiple Sclerosis
- Tramiprosate (ALZHEMED) North American Phase III clinical trial progress update
- CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
- Alseres Pharmaceuticals Announces FDA Clearance to Increase Dose Level in Cethrin(R) Phase I/IIa Clinical Trial for Acute Spinal Cord Injury at U.S. Sites
- UCB and Biogen Idec’s oral VLA-4 antagonist (CDP323) enters phase II development for Multiple Sclerosis
- Exelon®Patch, the first and only skin patch for the treatment of Alzheimer's disease, receives first worldwide approval in US
- Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 3454 Alzheimer's Disease Trial
- FDA Approves Demipulse And Demipulse Duo Generators
- Patient Enrollment on Target in National Institutes of Health Phase III Parkinson’s Disease Trial
- Avicena to Proceed to Confirmatory Phase III
- Cortex to Resume Clinical Trial with AMPAKINE CX717 in Alzheimer-PET Scan Study After FDA Approves Protocol with Higher Doses of Drug
- Targacept Announces Initiation of Phase IIb Development of AZD3480 (TC-1734) for Alzheimer’s Disease
- Neurochem granted fast track designation from U.S. FDA for tramiprosate (ALZHEMED)
- BioMS Relapsing-Remitting MS Trial Receives Positive Review From Data Safety Monitoring Board
- Icagen Announces Filing of IND for ICA-105665, a Novel Compound for the Treatment of Epilepsy
- Targacept Initiates Phase I Clinical Trial of TC-5619
- Lexicon Drug Candidate For Cognitive Disorders Successfully Completes Phase 1 Clinical Trial
- Medivation Announces Treatment of First Patient in Phase 2 Trial of Dimebon in Huntington's Disease
- Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
- Lexicon Drug Candidate For Cognitive Disorders Successfully Completes Phase 1 Clinical Trial
- Prana today announced an update on its Phase IIa clinical trial of PBT2 in patients with Alzheimer’s disease.
- Stem Cell Therapeutics Opens Second Clinical Trial Site for Its Lead Stroke Program
- Sirtris Pharmaceuticals, Inc. Announces Initiation of Phase 1b Clinical Trial of SRT501 in MELAS
- Neurochem announces results from tramiprosate (ALZHEMED™) North American Phase III clinical trial
- Ketasyn Improves Memory in Age-Associated Memory Impairment Study
- Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
- Transition Therapeutics Announces Completion of Phase I Clinical Studies with Alzheimer\'s Disease Drug Candidate ELND-005/AZD-103
- Avigen Initiates European Multi-Center AV650 Phase II Spasticity Trial in Patients with Multiple Sclerosis
- Icagen Announces Initiation of Phase I Study of ICA-105665, a Novel Compound for the Treatment of Epilepsy
- OVATION FURTHER ADVANCES DEVELOPMENT PIPELINE WITH NEW PHASE III EPILEPSY STUDY
- ATL1102 MS Phase IIa Trial Update
- Opexa Therapeutics Gives Update on Phase IIb Trial of Tovaxin® for Treatment of Multiple Sclerosis
- SYGNIS’ AX200 shows efficacy in stroke patients – Phase IIa results exceed expectations
- Neuren completes moderate TBI Phase 1b safety trial of NNZ-2566
- Exelon® patch receives European Union approval, the first skin patch therapy to treat Alzheimer\'s disease
- CytRx Provides Arimoclomol and Iroxanadine Clinical Trial Updates
- Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704
- Prana Completes Enrollment in Phase IIa Trial of PBT2 in Alzheimer’s Disease Patients
- Alseres Pharmaceuticals\' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
- Alseres Pharmaceuticals\' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
- Santhera Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich\'s Ataxia and Provides Details on Study Design
- Santhera Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich\'s Ataxia and Provides Details on Study Design
- NeuroSearch files Clinical Trial Application for the initiation of a clinical Phase III programme with ACR16 in Huntington’s disease in Europe